LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

Photo by sharonmccutcheon from unsplash

Nonacog beta pegol (N9‐GP) is a glycoPEGylated recombinant factor IX (FIX) with an extended half‐life developed for routine prophylaxis and the prevention and treatment of bleeding episodes in patients with… Click to show full abstract

Nonacog beta pegol (N9‐GP) is a glycoPEGylated recombinant factor IX (FIX) with an extended half‐life developed for routine prophylaxis and the prevention and treatment of bleeding episodes in patients with haemophilia B.

Keywords: extended half; patients haemophilia; beta pegol; nonacog beta; half life

Journal Title: Haemophilia
Year Published: 2017

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.